Smart Nanomaterials Could Finally Heal the Wounds That Refuse to Close

Chronic wounds are one of medicine’s quietest crises. Millions of people worldwide live with ulcers that refuse to close, and the economic toll of their prolonged hospitalization and ongoing care often exceeds that of certain cancers. A comprehensive new review published in Results in Chemistry by Mahnaz Amiri, Muhammad Hossein Ashoub, Sahar Zinatloo-Ajabshir, and Fatemeh Divsalare maps out how nano-architectured materials could change that picture, linking specific nanoscale designs to the molecular failures that keep diabetic foot ulcers, pressure sores, and infected wounds stuck in a destructive loop.

The biology of a stalled wound is strikingly different from that of a healthy one. Normal healing proceeds through four coordinated stages: hemostasis, inflammation, proliferation, and remodeling, orchestrated by a cast of cells and growth factors. Chronic wounds, particularly diabetic foot ulcers, are trapped in a hostile microenvironment defined by elevated reactive oxygen species (ROS), persistent bacterial biofilms, hypoxia, and an overabundance of matrix metalloproteinases that chew through the extracellular matrix. In diabetes, hyperglycemia drives the formation of advanced glycation end-products, which fuel chronic inflammation and further oxidative stress. Infections by Staphylococcus aureus and Pseudomonas aeruginosa deepen the problem, colonizing tissue, prolonging inflammation, and impairing the clotting and angiogenesis processes the wound needs to recover.

Conventional care has not kept pace with this complexity. Debridement, the surgical or enzymatic removal of dead tissue, remains the gold standard for cleaning the wound bed, but it is painful, requires skilled surgeons, and does nothing to correct the underlying biochemistry. Autologous skin grafts still deliver the best cosmetic and functional outcomes, yet donor sites are limited, and even engineered skin substitutes fall short of a complete replacement. Topical growth factors and antimicrobials help, but wound exudates rapidly degrade free drugs. The review’s central argument is that advanced materials must do more than cover a wound: they must actively modulate the microenvironment, scavenging excess ROS, delivering growth factors intact, and dismantling biofilms.

Natural polymers form the backbone of many next-generation dressings precisely because they speak the body’s language. Collagen, roughly 30 percent of animal protein, provides a triple-helical scaffold that supports cell attachment, induces coagulation, and releases bioactive peptides with immunomodulatory, antibacterial, and antioxidative activity. Silk fibroin from the Bombyx mori silkworm offers antimicrobial properties, moisture retention, gas exchange, and negligible immunogenicity. Keratin, long overlooked as a therapy, has recently attracted attention: keratin 17 surges at wound margins after injury, and mice lacking it heal poorly, while keratin-derived dressings accelerated epithelialization in pig models. Alginate from brown seaweed absorbs exudates and keeps the wound moist, and hyaluronic acid, a glycosaminoglycan of the extracellular matrix, actively promotes angiogenesis, though it must be blended with other macromolecules for mechanical strength.

Synthetic and hybrid systems address the weaknesses of natural polymers, which suffer from batch-to-batch variability and poor mechanical consistency. Polyurethane films, hydrogels, foams, and hydrocolloids can be engineered with reproducible properties, and the review highlights work showing polyurethane dressings producing thinner scabs and earlier vascularized granulation tissue than a commercial control. The authors argue that hybrid composite scaffolds combining natural bioactivity with synthetic reliability represent the optimal strategy for clinical translation, a theme that recurs throughout their functional classification of biomaterial platforms.

The most technically rich section of the review concerns nanoparticles themselves. Silver nanomaterials, already commercialized in dressings such as Acticoat, kill bacteria by deactivating enzymes, modifying thiol groups on cysteine residues, and generating ROS; proteomic studies show they disable outer-membrane proteins in E. coli and block proton transfer, starving cells of ATP. Zinc oxide nanoparticles exploit size-dependent effects, entering bacterial cells through nanometer-scale surface pores and producing hydrogen peroxide and ROS that also stimulate fibroblast growth. Gold nanoparticles, particularly when paired with light stimulation or antioxidants like epigallocatechin gallate, enhanced keratinocyte and fibroblast proliferation and angiogenic signaling in animal studies. Copper nanoparticles, notably two-and-a-half to six times less toxic than copper salts, address the trace-metal deficits that slow healing.

Emerging materials aim directly at the diabetic wound’s oxidative chaos. Cerium oxide nanoparticles mimic the enzymes superoxide dismutase and catalase, neutralizing ROS while activating the PI3K/Akt and Wnt/beta-catenin pathways that drive endothelial cell proliferation and new blood vessel formation. When conjugated with microRNA-146a or embedded in gelatin methacryloyl hydrogels, they reduce inflammation and accelerate closure without antibiotics. Silica nanoparticles release silicic acid that promotes fibroblast migration, and mesoporous versions serve as high-capacity drug carriers. Self-assembling peptide nanostructures offer cytocompatible, non-immunogenic scaffolds that can be tailored with cell-adhesion epitopes. Carbon-based materials round out the arsenal: fullerenes scavenge reactive oxygen and nitrogen species, graphene oxide encourages keratinocyte migration and angiogenesis, and carbon nanotubes composited with chitosan enhanced collagen deposition in vivo.

Delivery architecture matters as much as the therapeutic cargo. Polymeric nanoparticles made of PLGA protect drugs from wound proteases and release them in a sustained fashion; LL37-loaded PLGA particles promoted cell migration and granulation in full-thickness wound models. Liposomes and niosomes carry both hydrophilic and lipophilic agents, and a silk-fibroin-cored liposome preserved basic fibroblast growth factor in wound secretions while accelerating angiogenesis. Solid lipid nanoparticles and nanostructured lipid carriers achieved high encapsulation efficiency and superior stability, delivering recombinant human EGF to diabetic mice with marked improvements in re-epithelialization. Electrospun nanofibers mimic the extracellular matrix’s topography, coaxial variants sustaining drug release for up to 30 days, while nanohydrogels absorb exudate, admit oxygen, and can be loaded with stimuli-sensitive cargo.

The next generation of dressings is designed to think. pH-responsive nanofibers signal and treat infection, since chronic and infected wounds trend alkaline. Thermoresponsive meshes with biodegradable metallic heaters release drugs on demand, enzyme-responsive systems degrade in the presence of overexpressed matrix metalloproteinases or bacterial lipases, and ROS-cleavable hydrogels unload anti-inflammatory payloads exactly where oxidative stress reigns. The review frames this as a shift from passive, one-size-fits-all coverage toward personalized, dynamic therapy, though it cautions that manufacturing complexity and sensor stability in the harsh wound bed remain significant hurdles.

The translational roadmap is candid about where each technology stands. Drug-loaded dressings built on FDA-approved polymers with established metals like silver and zinc oxide, plus lipid nanoparticles, are closest to the clinic because regulatory pathways already exist. Cerium oxide platforms and smart stimuli-responsive hydrogels, despite immense promise for diabetic wounds, still need extensive long-term toxicity and biodistribution data, since silver accumulation illustrates the risks of established materials. The authors call for rigorous nanotoxicology monitoring, scalable manufacturing including 3D and 4D bioprinting of nanocomposite scaffolds, and point-of-care diagnostics that analyze wound exudate to prescribe multifunctional dressings matched to each patient’s microenvironment. If those pieces come together, the stubborn ulcers that medicine has managed for decades may finally be engineered to heal.

Subject of Research: Nano-architected biomaterials and smart drug delivery systems for chronic and diabetic wound healing

Article Title: Nano-architectures in wound healing: Smart delivery systems, mechanistic insights, and translational roadmap

Article References: Nano-architectures in wound healing: Smart delivery systems, mechanistic insights, and translational roadmap. (n.d.). https://doi.org/10.1016/j.rechem.2026.103803

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103803

Keywords: nanotechnology, wound healing, diabetic foot ulcers, nanoparticles, cerium oxide, silver nanoparticles, hydrogels, drug delivery, electrospun nanofibers, ROS scavenging, biomaterials, smart dressings